Amgen's Q1 2024 earnings call highlights strong revenue growth and a robust pipeline, particularly in the rare disease and oncology sectors.  Positive data for MariTide in Phase II obesity trials supports plans for a broad Phase III program.  Management's focus on differentiated medicines and rapid advancement of tarlatamab and other promising pipeline candidates suggests a bullish outlook for the next few weeks.
[1]
